Friday, July 10, 2026

pharma · Diphtheria · Diabetes Mellitus, Type 2

Sanofi Pasteur MSD

Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini

France, LYON HQ
363 Employees
EMA registrant Type
Company details
Status
Public
HQ
France, LYON
Employees
363
Programs
83
Drugs
66
Patents
0
Clinical program

Enoxaparin

Approved · small molecule · Acute Illness

Enoxaparin for Acute Illness is a Approved program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).

← All Sanofi Pasteur projects Approved small molecule completed

Internal code ENOXA_C_01249

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sanofi Pasteur
Phase
Approved
Modality
small_molecule
Indication
Acute Illness
Status
completed
Trials
1

Clinical trials